Related Experiment Video
Updated: Feb 19, 2026

Serum and Plasma Copy Number Detection Using Real-time PCR
Published on: December 15, 2017
Letter--Corrected Net Health Benefit Calculations for Enzalutamide Using ASCO Value Framework Guidelines and NCCN
Scott Flanders1, Bruce Brown2, Marjan Massoudi3
11 Senior Director, Health Economics and Outcomes Research-Oncology Astellas Pharma.
Disclosures:
This research was funded by Astellas Pharma and Medivation, which was acquired by Pfizer in 2016. Astellas Pharma and Medivation are the co-developers of enzalutamide. Flanders, Brown, Massoudi, and Schultz are employees of Astellas Pharma. Ramaswamy is an employee of Pfizer and holds stock in Johnson & Johnson. Flanders holds stock in Johnson & Johnson, AbbVie, and Abbott Labs.
More Related Videos
Related Concept Videos
Standards of Care II
Standards of Care I
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Cancer Survival Analysis

